Nellcor gains respiratory products in Puritan-Bennett deal
This article was originally published in Clinica
Nellcor will take over Puritan-Bennett in a stock-for-stock transaction worth about $475 million. The deal will combine worldwide leaders in two complementary areas - patient monitoring and respiratory therapy - Nellcor says. The new company, Nellcor/Puritan-Bennett, will provide a line of products to diagnose, monitor and treat patients with respiratory difficulties in the hospital, alternative care sites and the home.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.